Roof Eidam Maycock Peralta LLC Has $539,000 Stock Position in Koninklijke Philips (NYSE:PHG)

Roof Eidam Maycock Peralta LLC decreased its holdings in shares of Koninklijke Philips (NYSE:PHG) by 31.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 16,470 shares of the technology company’s stock after selling 7,494 shares during the period. Roof Eidam Maycock Peralta LLC’s holdings in Koninklijke Philips were worth $539,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of PHG. Mondrian Investment Partners LTD boosted its holdings in shares of Koninklijke Philips by 45.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 9,553,058 shares of the technology company’s stock worth $191,061,000 after buying an additional 2,971,008 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Koninklijke Philips by 27.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,036,336 shares of the technology company’s stock valued at $101,718,000 after purchasing an additional 864,951 shares during the period. Russell Investments Group Ltd. boosted its holdings in Koninklijke Philips by 36.4% in the 1st quarter. Russell Investments Group Ltd. now owns 1,410,067 shares of the technology company’s stock valued at $28,201,000 after purchasing an additional 376,244 shares during the period. Millennium Management LLC boosted its holdings in Koninklijke Philips by 822.0% in the 2nd quarter. Millennium Management LLC now owns 1,120,521 shares of the technology company’s stock valued at $28,237,000 after purchasing an additional 998,995 shares during the period. Finally, Natixis Advisors LLC boosted its holdings in Koninklijke Philips by 5.2% in the 2nd quarter. Natixis Advisors LLC now owns 930,085 shares of the technology company’s stock valued at $23,438,000 after purchasing an additional 46,268 shares during the period. Institutional investors and hedge funds own 13.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Monday, July 15th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Koninklijke Philips presently has an average rating of “Hold”.

Koninklijke Philips Trading Up 0.3 %

Shares of Koninklijke Philips stock opened at $32.15 on Tuesday. The stock has a market capitalization of $30.22 billion, a P/E ratio of -33.49, a price-to-earnings-growth ratio of 1.06 and a beta of 0.74. The company has a quick ratio of 0.74, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The company has a 50-day simple moving average of $30.85 and a 200 day simple moving average of $27.46. Koninklijke Philips has a 12-month low of $18.06 and a 12-month high of $32.91.

Koninklijke Philips (NYSE:PHG) last announced its earnings results on Monday, July 29th. The technology company reported $0.32 earnings per share (EPS) for the quarter. The business had revenue of $4.80 billion during the quarter. Koninklijke Philips had a negative net margin of 2.35% and a positive return on equity of 10.15%. Research analysts expect that Koninklijke Philips will post 1.59 earnings per share for the current fiscal year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.